24/7 Market News Snapshot 20 October, 2025 – SciSparc Ltd. Ordinary Shares (NASDAQ:SPRC)

October 20, 2025

DENVER, Colo., 20 October, 2025 (www.247marketnews.com) – (NASDAQ:SPRC) are discussed in this article.
SciSparc Ltd. (NASDAQ:SPRC) is currently witnessing a significant bullish trend, with shares trading at $4.440 in the pre-market, representing a striking 16.23% increase from the previous closing price of $3.820. This surge reflects strong investor interest, likely fueled by recent positive developments concerning the company’s innovative treatment strategies. With a current trading volume of 1.40 million shares, robust market participation indicates both momentum and active engagement from investors. As the share price nears recent highs, it is essential for market participants to monitor potential resistance levels and consider breakout opportunities in this dynamic trading environment.

In conjunction with this momentum, SciSparc announced a pivotal advancement in its collaboration with Clearmind Medicine Inc. The U.S. Patent and Trademark Office has published a patent application detailing a novel combination therapy using MEAI (5-methoxy-2-aminoindane) and N-Acylethanolamines, particularly Palmitoylethanolamide (PEA). This pioneering patent aims to address a wide range of binge behavior disorders, including alcohol dependence, eating disorders, tobacco addiction, and compulsive behaviors.

By leveraging the psychedelic properties of MEAI to enhance management of impulsivity and reward-seeking behavior, combined with PEA’s recognized anti-inflammatory and neuroprotective benefits, the collaboration aims to create more effective and safer therapeutic options than conventional treatments. Preclinical studies have already indicated promising results in reducing binge episodes while preserving natural reward pathways.

Through these initiatives, SciSparc is committed to expanding its repertoire of cannabinoid-based therapies, as it develops solutions targeting critical conditions such as Tourette Syndrome, agitation related to Alzheimer’s disease, autism, and status epilepticus. The recent patent publication signifies a substantial step in addressing significant yet often overlooked behavioral challenges, reaffirming SciSparc’s dedication to advancing impactful therapeutic solutions. Anticipation grows as both SciSparc and Clearmind continue their collaboration towards potential market introduction of these innovative treatments.

Related news for (SPRC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.